LENZ Therapeutics (LENZ) Operating Expenses (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Operating Expenses of $46.0 million for Q1 2026, up 171.9% year-over-year from $16.9 million in Q1 2025, and up 14.94% quarter-over-quarter from $40.1 million in Q4 2025.
LENZ Therapeutics (LENZ) Operating Expenses (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Operating Expenses for 7 consecutive years, with $46.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 171.9% year-over-year to $46.0 million; the TTM figure through Mar 2026 stood at $139.3 million (up 134.35% YoY), while the FY2025 annual figure was $110.2 million, up 88.07% from the prior year.
- Operating Expenses rose to $46.0 million in Q1 2026 per LENZ's latest filing, from $40.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $46.0 million in Q1 2026 and bottomed at $12.6 million in Q1 2023.
- Historically, Operating Expenses has averaged $23.1 million across 5 years, with a median of $21.9 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 177.09% — and 2023, when it slumped 51.4%.
- LENZ Therapeutics' Operating Expenses stood at $26.8 million in 2022, then retreated by 6.59% to $25.0 million in 2023, then plunged by 39.07% to $15.2 million in 2024, then jumped by 163.06% to $40.1 million in 2025, then climbed by 14.94% to $46.0 million in 2026.
- Business Quant data shows LENZ's Operating Expenses at $46.0 million in Q1 2026, $40.1 million in Q4 2025, and $31.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | LENZ Therapeutics | 146.20 Mn | 146.20 Mn | 5.21 Mn | 39.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.66 Mn |
| Mar 31, 2026 | 46.04 Mn |
| Dec 31, 2025 | 40.05 Mn |
| Sep 30, 2025 | 31.39 Mn |
| Jun 30, 2025 | 21.86 Mn |
| Mar 31, 2025 | 16.93 Mn |
| Dec 31, 2024 | 15.23 Mn |
| Sep 30, 2024 | 12.95 Mn |
| Jun 30, 2024 | 14.35 Mn |
| Mar 31, 2024 | 16.09 Mn |
| Dec 31, 2023 | 24.99 Mn |
| Sep 30, 2023 | 19.87 Mn |
| Jun 30, 2023 | 14.96 Mn |
| Mar 31, 2023 | 12.62 Mn |
| Dec 31, 2022 | 26.75 Mn |
| Sep 30, 2022 | 26.15 Mn |
| Jun 30, 2022 | 26.78 Mn |
| Mar 31, 2022 | 25.96 Mn |
| Dec 31, 2021 | 18.94 Mn |
| Sep 30, 2021 | 14.60 Mn |